What is EXEL's market cap?

$17.75B, based on the Nov 4 close of $72.75.

What is EXEL's P/E ratio?

20.1× trailing-twelve-month earnings of $885.14M.

Does Exelixis pay a dividend?

No regular cash dividend has been paid in the last year.

How much of EXEL is sold short?

27.3M shares, 11.4% of float, as of Oct 15, 2026.

What sector is EXEL in?

Healthcare, in the Biotechnology industry.

NASDAQ · EXELHealthcareBiotechnology

Exelixis Inc (EXEL)

$72.75+0.61%

Close Nov 4, 2026 · split-adjusted

Nov 3, 2026$72.31▲ 89.99% in range

Nov 3, 2025Low $37.90 · High $72.31Nov 3, 2026

What changed · written from our data

As of Nov 4, 2026

Exelixis closed at $72.75 on Nov 4, up 0.61% — matching its 52-week closing high. Volume of 3.0M shares was 1.14× its 20-day average (close to normal).

Split-adjusted performance: +24.7% over one month, +49.4% over six months, +91.1% over one year.

In the quarter ended Oct 2, 2026, revenue was $658.70M, up 10.2% from a year earlier, with a net margin of 33.1%.

Short interest was 27.3M shares at the Oct 15 settlement, down 3.1% from the prior report (11.4% of float, 11.3 days to cover).

Market cap$17.75B244.0M shares

Revenue · quarter$658.7M+10.2% YoY

Diluted EPS$0.85+23.2% YoY

P/E · TTM20.1×P/S 7.1×

Net margin33.1%Gross 96.0%

Dividend yieldNone

52-week range37.90 – 72.750.0% from high

Volume3.0M1.14× 20-day avg

Volatility · 60d25.7%Annualised

Short % of float11.4%11.3 days to cover

Net cash$892.0MCash $892.0M

Next earnings—Not scheduled

Split-adjusted performance

1W +9.8%1M +24.7%3M +39.4%6M +49.4%YTD +66.0%1Y +91.1%3Y +259.4%5Y +241.5%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum90

Revenue growth56

Net margin88

Value (low P/E)54

Size96

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →

Shares short27.3M−3.1% vs prior

Days to cover11.3Settled Oct 15

% of float11.4%

Short vol. 10d56.6%of daily volume

Closest peers by size in Biotechnology

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
EXELExelixis	$72.75	+0.61%	+49.4%	+10.2%	33.1%	20.1	$17.75B
NBIXNeurocrine Biosciences	$166.05	+0.73%	+12.9%	+41.2%	18.4%	24.0	$16.88B	Compare
HALOHalozyme Therapeutics	$130.34	+1.34%	+96.4%	+47.7%	47.8%	35.8	$14.79B	Compare
KYMRKymera Therapeutics	$136.25	+7.21%	+58.0%	−100.0%	—	—	$11.63B	Compare
TECHBio-Techne	$72.73	+0.10%	+53.4%	+1.3%	17.0%	62.8	$11.42B	Compare
RGENRepligen	$178.20	−0.04%	+41.7%	+10.9%	−18.4%	—	$11.31B	Compare
PCVXVaxcyte	$65.68	+8.01%	+15.0%	—	—	—	$10.34B	Compare
IBRXImmunityBio	$8.93	+7.72%	+6.6%	+93.9%	−449.6%	—	$9.46B	Compare
TWSTTwist Bioscience	$142.58	+1.63%	+139.5%	+23.2%	−29.6%	—	$9.45B	Compare

News about Exelixis

All news →

EXEL Q3 Earnings Beat Estimates on Strong Cabometyx SalesZacks Investment Research · 5d ago▲ Positive Exelixis (EXEL) Q3 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research · 6d agoNeutral Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research · Oct 22, 2026▲ Positive Why Exelixis (EXEL) is a Top Growth Stock for the Long-TermZacks Investment Research · Oct 16, 2026▲ Positive Why Exelixis (EXEL) is Poised to Beat Earnings Estimates AgainZacks Investment Research · Oct 15, 2026▲ Positive

Quick answers

What does Exelixis do?: Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx.
What is EXEL's market cap?: $17.75B, based on the Nov 4 close of $72.75.
What is EXEL's P/E ratio?: 20.1× trailing-twelve-month earnings of $885.14M.
Does Exelixis pay a dividend?: No regular cash dividend has been paid in the last year.
How much of EXEL is sold short?: 27.3M shares, 11.4% of float, as of Oct 15, 2026.
What sector is EXEL in?: Healthcare, in the Biotechnology industry.

About Exelixis

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

HQ: Alameda, CA1,077 employeesListed Apr 11, 2000exelixis.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology